CING

+ Watchlist + Portfolio

Cingulate Inc.

Regulated industry Physical products Development stageTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $4.75
52-Week Range: $3.16 – $11.89
Market Cap: $69.22M
P/E (TTM): —
EPS (TTM): -3.51
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 2.82
PEG Ratio: —
Return on Equity: -198.74%
Return on Assets: -66.94%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 3.50
Debt/Equity: 0.27
Total Debt: $6.29M
Free Cash Flow: $-12.84M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $47.11M

CING Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00	$0.00
Research & Development	$9.00M	$15.49M	$9.45M	$9.77M
Selling, General & Admin	$8.51M	$7.27M	$6.20M	$10.16M
Operating Expenses	$17.50M	$22.76M	$15.65M	$19.94M
Operating Income	-$17.50M	-$22.76M	-$15.65M	-$19.94M
EBITDA	-$17.11M	-$22.18M	-$14.99M	-$19.40M
Pretax Income	-$17.68M	-$23.53M	-$16.56M	-$22.45M
Income Tax	$0.00	$0.00	$0.00	$0.00
Net Income	-$17.68M	-$23.53M	-$16.56M	-$22.45M
Diluted EPS	-374.40	-311.99	-4.57	-4.44
Diluted Shares	47212	75435	3.40M	5.06M

CING Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$5.36M	$52.42K	$12.21M	$10.95M
Receivables	$234.43K	$14.62K	$26.32K	$8.01K
Current Assets	$7.87M	$578.59K	$12.66M	$12.01M
Total Assets	$11.41M	$3.49M	$14.86M	$15.07M
Current Liabilities	$7.01M	$10.23M	$4.97M	$10.31M
Long-Term Debt	—	—	$2.44M	$1.15M
Total Debt	$5.87M	$3.51M	$5.10M	$8.79M
Total Liabilities	$7.52M	$10.36M	$7.41M	$12.56M
Retained Earnings	-$69.41M	-$92.94M	-$109.93M	-$132.38M
Shareholders' Equity	$3.88M	-$6.87M	$7.46M	$2.51M
Working Capital	$856.85K	-$9.65M	$7.69M	$1.70M
Net Debt	—	$2.95M	—	—

CING Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$15.88M	-$15.03M	-$18.45M	-$17.25M
Capital Expenditure	-$153.42K	-$224.10K	-$211.80K	-$162.14K
Free Cash Flow	-$16.04M	-$15.26M	-$18.66M	-$17.41M
Depreciation & Amortisation	$394.01K	$582.92K	$653.09K	$540.89K
Stock-Based Compensation	$800.80K	$812.67K	$995.48K	$1.52M
Investing Cash Flow	-$152.65K	-$224.10K	-$211.80K	-$162.14K
Financing Cash Flow	$4.90M	$9.95M	$30.82M	$16.15M
Net Change in Cash	-$11.14M	-$5.30M	$12.16M	-$1.26M

CING Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$2.22M	$2.70M	$2.85M	$2.00M	$2.18M	$1.49M
Selling, General & Admin	$1.48M	$1.95M	$3.15M	$3.58M	$5.74M	$3.93M
Operating Expenses	$3.71M	$4.65M	$6.00M	$5.59M	$7.92M	$5.41M
Operating Income	-$3.71M	-$4.65M	-$6.00M	-$5.59M	-$7.92M	-$5.41M
EBITDA	-$3.54M	-$4.50M	-$5.89M	-$5.46M	-$7.80M	-$5.32M
Pretax Income	-$3.85M	-$4.98M	-$7.34M	-$6.27M	-$9.31M	-$5.87M
Income Tax	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Net Income	-$3.85M	-$4.98M	-$7.34M	-$6.27M	-$9.31M	-$5.87M
Diluted EPS	-1.04	-1.14	-1.35	-0.87	-0.95	-0.45
Diluted Shares	3.66M	4.39M	5.43M	7.25M	9.78M	13.19M

CING Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$9.52M	$8.90M	$6.12M	$10.95M	$25.89M	$28.40M
Receivables	$41.57K	$19.59K	$19.04K	$8.01K	$53.94K	$38.45K
Current Assets	$10.50M	$10.22M	$7.43M	$12.01M	$27.91M	$30.21M
Total Assets	$12.47M	$13.47M	$10.52M	$15.07M	$30.86M	$33.07M
Current Liabilities	$5.62M	$6.73M	$5.88M	$10.31M	$10.96M	$8.63M
Long-Term Debt	$923.70K	—	—	$1.15M	—	—
Total Debt	$5.08M	$6.58M	$4.58M	$8.79M	$7.43M	$6.29M
Total Liabilities	$6.54M	$7.96M	$7.05M	$12.56M	$12.00M	$9.60M
Retained Earnings	-$112.29M	-$117.08M	-$126.10M	-$132.38M	-$141.69M	-$147.56M
Shareholders' Equity	$5.93M	$5.51M	$3.47M	$2.51M	$18.86M	$23.47M
Working Capital	$4.89M	$3.49M	$1.55M	$1.70M	$16.95M	$21.58M

CING Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$4.61M	-$4.80M	-$4.24M	-$3.60M	-$6.91M	-$5.90M
Capital Expenditure	—	—	—	-$156.21K	-$61.18K	-$67.08K
Free Cash Flow	-$4.61M	-$4.80M	-$4.24M	-$3.75M	-$6.97M	-$5.97M
Depreciation & Amortisation	$165.29K	$146.99K	$106.78K	$121.83K	$121.19K	$98.24K
Stock-Based Compensation	$357.65K	$187.39K	$592.82K	$385.96K	$593.10K	$362.23K
Investing Cash Flow	$0.00	-$5.92K	$0.00	-$156.21K	-$61.18K	-$67.08K
Financing Cash Flow	$1.92M	$4.18M	$1.46M	$8.59M	$21.91M	$8.48M
Net Change in Cash	-$2.69M	-$618.78K	-$2.78M	$4.83M	$14.94M	$2.51M

Market Snapshot

About

Cingulate Inc. is a biopharmaceutical company focused on developing treatments for attention-deficit/hyperactivity disorder (ADHD) and anxiety disorders. The company's lead product candidate uses a proprietary drug delivery technology called Precision Timed Release (PTR) to provide improved pharmacokinetic profiles for stimulant medications. Headquartered in Kansas City, Missouri, Cingulate aims to address limitations of existing ADHD treatments by offering more consistent medication delivery throughout the day. The company is conducting clinical trials to advance its product candidates through regulatory approval processes.